0001209191-22-006363.txt : 20220202
0001209191-22-006363.hdr.sgml : 20220202
20220202161809
ACCESSION NUMBER: 0001209191-22-006363
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220131
FILED AS OF DATE: 20220202
DATE AS OF CHANGE: 20220202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heerma Peter
CENTRAL INDEX KEY: 0001789617
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 22583882
MAIL ADDRESS:
STREET 1: C/O RETROPHIN, INC.
STREET 2: 3721 VALLEY CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-31
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001789617
Heerma Peter
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Commercial Officer
Common Stock
2022-01-31
4
A
0
9840
0.00
A
68422
D
Common Stock
2022-01-31
4
S
0
1125
27.40
D
67297
D
Employee stock option (right to buy)
27.50
2022-01-31
4
A
0
39360
0.00
A
2032-01-30
Common Stock
39360
39360
D
Performance-based restricted stock units
2022-01-31
5
A
0
E
9840
0.00
A
Common Stock
9840
9840
D
Performance-based restricted stock units
2022-01-31
5
A
0
E
8000
0.00
A
Common Stock
8000
8000
D
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.
This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2022-02-02